ACRS
Aclaris Therapeutics, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$6.17
+3.70%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 8.2M | 7.8M | 18.7M | 31.2M | 29.8M |
| Cost of Revenue | 361.0K | 2.1M | 2.8M | 18.1M | 12.0M |
| Gross Profit | 7.9M | 5.7M | 15.9M | 13.2M | 17.8M |
| Operating Expenses | |||||
| R&D Expense | 64.1M | 52.6M | 33.6M | 98.4M | 77.8M |
| SG&A Expense | 23.2M | 22.0M | 22.2M | 31.1M | 25.1M |
| General & Admin Expense | 23.2M | 22.0M | 22.2M | 31.1M | 25.1M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 6.8M | 7.5M | 102.1M | (19.0M) | 4.7M |
| Total Operating Expenses | 94.2M | 82.1M | 157.9M | 110.5M | 107.6M |
| Cost and Expenses | 94.5M | 84.2M | 160.7M | 128.6M | 119.6M |
| Operating Income (EBIT) | (86.3M) | (76.4M) | (141.9M) | (97.4M) | (89.9M) |
| Non-Operating | |||||
| Interest Income | 6.7M | 7.6M | 8.0M | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 6.7M | 7.6M | 8.0M | — | — |
| Other Non-Op Income/Expense | 10.6M | 11.5M | 9.9M | 8.5M | 2.9M |
| Non-Operating Income (excl Interest) | (10.6M) | (11.5M) | (89.4M) | 19.0M | (4.7M) |
| EBT (Pre-Tax Income) | (75.7M) | (64.9M) | (132.1M) | (88.8M) | (86.9M) |
| Income Tax Expense | — | — | — | (367.0K) | — |
| Bottom Line | |||||
| Net Income | (75.7M) | (64.9M) | (132.1M) | (88.5M) | (86.9M) |
| Earnings from Cont. Ops | (75.7M) | (64.9M) | (132.1M) | (88.5M) | (86.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (75.7M) | (64.9M) | (132.1M) | (88.5M) | (86.9M) |
| Per Share | |||||
| Basic EPS | ($0.58) | ($0.53) | ($1.71) | ($1.27) | ($1.33) |
| Diluted EPS | ($0.58) | ($0.53) | ($1.71) | ($1.27) | ($1.33) |
| Revenue Per Share | $0.06 | $0.06 | $0.24 | $0.45 | $0.46 |
| Shares | |||||
| Basic Shares Outstanding | 142.7M | 122.7M | 77.3M | 69.8M | 65.2M |
| Diluted Shares Outstanding | 142.7M | 122.7M | 77.3M | 69.8M | 65.2M |
| Profitability Metrics | |||||
| EBITDA | (75.1M) | (64.5M) | (51.7M) | (115.5M) | (84.4M) |
| D&A | 623.0K | 454.0K | 807.0K | 863.0K | 797.0K |
| EBIT | (75.7M) | (64.9M) | (52.5M) | (116.3M) | (85.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026